Press release
August 6, 2026
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
Braveheart Bio, Inc. (BRVE)
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized